|
Our current collaborations include the following:
- Novartis Pharmaceuticals Corporation — An agreement for the co-promotion and co-development of Enablex® (darifenacin) extended release tablets for the treatment of overactive bladder (OAB) in the United States.
- sanofi-aventis — A global alliance, except in Japan, to develop and commercialize Actonel® (risedronate sodium tablets), a treatment for osteoporosis.
- Watson Laboratories, a subsidiary of Watson Pharmaceuticals, Inc. — Collaborating on the development of transdermal testosterone products for women.
Out-Licensing
- Ajinomoto Co Inc. — developing and marketing risedronate for osteoporosis in Japan
Sub-licenses
- Takeda Pharmaceutical Co., Ltd.
- Eisai Co., Ltd.
- Dainippon Sumitomo Pharmaceuticals Inc — developing and marketing Didronel® (etidronate disodium) for osteoporosis in Japan
- Taigen — Developing an antibiotic licensed to them by P&G Pharmaceuticals.
Acquisitions
| 1982: |
 |
Acquisition of Norwich-Eaton Pharmaceuticals |
|
| 1986: |
|
Purchase of Nativelle Laboratories in France |
|
| 1992: |
|
Acquisition of Rohm Pharma, a German joint venture originally formed by Norwich-Eaton and Rohm Chemical |
|
| 1993: |
|
Purchase of Smith Kline & French SpA in Italy |
|
| 2004: |
|
Acquisition of Grupo Vita in Spain |
|
